Chang, Lijia
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H02846)
Article History
Received: 4 July 2022
Revised: 17 August 2022
Accepted: 22 August 2022
First Online: 13 September 2022
Competing interests
: KH is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, and “TGF-β1 in the treatment of depression” by the Chiba University. KH has also received speakers’ honoraria, consultant fee, or research support from Abbott, Boehringer Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Sumitomo-Pharma, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience. LC declares no conflict of interest.